FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W55125670> ?p ?o ?g. }

• W55125670 startingPage "883" @default.
• W55125670 abstract "I. INTRODUCTION For last twenty years, mass toxic tort litigation has dominated academic, judicial, and public policy debate over product liability litigation. Scholars chronicled civil justice system's response to mass litigation arising out of exposure to asbestos1 and Agent Orange,2 and use of pharmaceutical products and medical devices, including Bendectin,3 blood factor concentrate,4 intrauterine contraceptive devices,5 and silicone gel breast implants.6 Appellate opinions discussed impact of mass litigation procedures on corporate decision-making. Legal ethicists debated fairness of mass settlements. Journalists highlighted role of larger-than-life (and richer than Croesus) mass tort plaintiff attorneys in shaping litigation.9 Committees of judges and practitioners debated how to mold civil procedure rules to fit mass tort cases.10 Risk analysts were asked to predict advent of mass tort,11 and practitioners nominated candidates for title.12 And in 2003, in perhaps most telling indicator of rise of mass tort litigation, John Grisham published King of Torts, story of a public defender who amasses millions when he colludes with a corporation to settle a (rather outlandish) mass product defect lawsuit. Then, quite recently, climate of legal opinion on mass toxic torts turned around. Asbestos litigation plummeted13 and silica litigation-often nominated as the next asbestos-was stopped in its tracks.14 Asbestos powerhouse firms splintered.15 Some attorneys who had specialized in defending mass toxic tort cases found their colleagues questioning their ability to contribute to their firms' future financial growth.16 decline in number of annual filings of new asbestos claims and widespread publicity surrounding Judge Janis Jack's dismissal of apparently fraudulent silica claims-coupled with a decline in new securities class action lawsuit filings17 and Merck's success to date in defending against personal injury claims associated with its now recalled blockbuster drug Vioxx18-seemed to some harbingers of a new era in mass toxic tort litigation. The future of mass torts and class action is very much in question, opined NYU law professor Geoffrey Miller.19 When, in December 2006, American Lawyer published an article headlined It's Over and written by Alison Frankel, a long time observer of mass tort phenomenon, some readers may well have believed that mass toxic tort litigation had run its course.20 In fact, Frankel did not assert that mass tort cases are disappearing from courts: There will always be people injured by products or actions of big corporations, and there's still money to be made representing them. But bonanza-the Wild West era in which mass torts was an unfettered frontier and plaintiffs lawyers seemed to have all firepower-is over. If you're a plaintiffs lawyer and you haven't already bought plane and yacht of your dreams, well, sorry, pal. You're too late.21 As indicators of end of an era in mass tort litigation, Frankel pointed to declining number of new asbestos claims filings, a more vigilant state and federal judiciary, and defendants' new determination to fight, rather than settle cases. She quoted Joseph Rice, a leading asbestos plaintiff lawyer: I do not believe next ten years will be a repeat of last ten . . . Congress will not allow another tobacco. [Presumably a reference to state attorneys' general litigation that his partner Ronald Motley spear-headed.] courts will not allow multiple-jurisdiction litigation over products.22 source of changes in judicial, legislative and defense attitudes, Frankel argued, was decades-long tort reform movement-and overreaching of plaintiff attorneys. 3 Has mass toxic tort litigation reached end of its life cycle? Having researched and written about this litigation for many years, my curiosity was provoked by Frankel's article and discussion it engendered among my fellow mass tort aficionados. …" @default.
• W55125670 created "2016-06-24" @default.
• W55125670 creator A5072413416 @default.
• W55125670 date "2007-09-01" @default.
• W55125670 modified "2023-09-26" @default.
• W55125670 title "Has the Fat Lady Sung? the Future of Mass Toxic Torts" @default.
• W55125670 hasPublicationYear "2007" @default.
• W55125670 type Work @default.
• W55125670 sameAs 55125670 @default.
• W55125670 citedByCount "3" @default.
• W55125670 countsByYear W551256702013 @default.
• W55125670 countsByYear W551256702014 @default.
• W55125670 crossrefType "journal-article" @default.
• W55125670 hasAuthorship W55125670A5072413416 @default.
• W55125670 hasConcept C144133560 @default.
• W55125670 hasConcept C17744445 @default.
• W55125670 hasConcept C199539241 @default.
• W55125670 hasConcept C200635333 @default.
• W55125670 hasConcept C2777134139 @default.
• W55125670 hasConcept C2777449729 @default.
• W55125670 hasConcept C2777834853 @default.
• W55125670 hasConcept C2779140086 @default.
• W55125670 hasConcept C57017900 @default.
• W55125670 hasConcept C97460637 @default.
• W55125670 hasConceptScore W55125670C144133560 @default.
• W55125670 hasConceptScore W55125670C17744445 @default.
• W55125670 hasConceptScore W55125670C199539241 @default.
• W55125670 hasConceptScore W55125670C200635333 @default.
• W55125670 hasConceptScore W55125670C2777134139 @default.
• W55125670 hasConceptScore W55125670C2777449729 @default.
• W55125670 hasConceptScore W55125670C2777834853 @default.
• W55125670 hasConceptScore W55125670C2779140086 @default.
• W55125670 hasConceptScore W55125670C57017900 @default.
• W55125670 hasConceptScore W55125670C97460637 @default.
• W55125670 hasIssue "4" @default.
• W55125670 hasLocation W551256701 @default.
• W55125670 hasOpenAccess W55125670 @default.
• W55125670 hasPrimaryLocation W551256701 @default.
• W55125670 hasRelatedWork W1490612697 @default.
• W55125670 hasRelatedWork W1492433108 @default.
• W55125670 hasRelatedWork W1986340334 @default.
• W55125670 hasRelatedWork W2045264865 @default.
• W55125670 hasRelatedWork W2087318849 @default.
• W55125670 hasRelatedWork W225850553 @default.
• W55125670 hasRelatedWork W2268835748 @default.
• W55125670 hasRelatedWork W2399014704 @default.
• W55125670 hasRelatedWork W2485381248 @default.
• W55125670 hasRelatedWork W2598084961 @default.
• W55125670 hasRelatedWork W297511208 @default.
• W55125670 hasRelatedWork W3122561011 @default.
• W55125670 hasRelatedWork W3123002638 @default.
• W55125670 hasRelatedWork W3123112816 @default.
• W55125670 hasRelatedWork W3123893193 @default.
• W55125670 hasRelatedWork W328045463 @default.
• W55125670 hasRelatedWork W336652853 @default.
• W55125670 hasRelatedWork W42344546 @default.
• W55125670 hasRelatedWork W3122585268 @default.
• W55125670 hasRelatedWork W3122719555 @default.
• W55125670 hasVolume "26" @default.
• W55125670 isParatext "false" @default.
• W55125670 isRetracted "false" @default.
• W55125670 magId "55125670" @default.
• W55125670 workType "article" @default.